Skip Navigation

Cardiovascular Research 1999 43(4):1029-1039; doi:10.1016/S0008-6363(99)00144-3
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shimokawa, H.
Right arrow Articles by Takeshita, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimokawa, H.
Right arrow Articles by Takeshita, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm

Hiroaki Shimokawaa,*, Minoru Setob, Naoki Katsumataa, Mutsuki Amanoc, Toshiyuki Kozaia, Tohru Yamawakia, Kouichi Kuwataa, Tadashi Kandabashia, Kensuke Egashiraa, Ichiro Ikegakib, Toshio Asanob, Kozo Kaibuchic and Akira Takeshitaa

aThe Research Institute of Angiocardiology and Cardiovascular Clinic, Kyushu University School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
bThe Life Science Center, Asahi Chemical Industry, Co. Ltd., Shizuoka 410-2321, Japan
cDivision of Signal Transduction, Nara Institute of Science and Technology, Ikoma 630-0101, Japan

* Corresponding author. Tel.: +81-92-642-5360; fax: +81-92-642-5374 shimo{at}cardiol.med.kyushu-u.ac.jp

Objective: We recently demonstrated in our swine model of coronary artery spasm that enhanced myosin light chain (MLC) phosphorylations (both MLC mono- and diphosphorylations) play a central role in the pathogenesis of the spasm. However, the molecular mechanism for and the phosphorylation sites for the enhanced MLC phosphorylations were unknown. In the present study, we addressed these points using hydroxyfasudil, a novel inhibitor of protein kinases, which we found preferentially inhibits Rho-kinase. Methods: The specificity of the inhibitory effects of hydroxyfasudil on Rho-kinase, MLCK, MRCKβ and PKC were examined by kinase assay in vitro. The left porcine coronary artery was chronically treated with interleukin-1β (IL-1β, 2.5 µg). Two weeks after the operation, coronary artery vasomotion was examined both in vivo and in vitro. MLC phosphorylations were examined by Western blot analysis and the sites for the phosphorylations by anti-phosphorylated MLC antibodies that identified the monophosphorylation site as Ser19 and diphophorylation sites as Ser19/Thr18 of MLC. Results: Inhibitory effects of hydroxyfasudil was at least 100 times more potent for Rho-kinase as compared with other protein kinases tested. Intracoronary serotonin (10 µg/kg) caused coronary hyperconstriction at the IL-1β-treated site in vivo, which was dose-dependently inhibited by hydroxyfasudil (p<0.01). The coronary segment taken from the spastic site also showed hypercontractions to serotonin in vitro, which were again dose-dependently inhibited by hydroxyfasudil (p<0.01). Western blot analysis showed that MLC monophosphorylation was significantly greater in the spastic segment than in the control segment, while MLC diphosphorylation was noted only at the spastic segment (p<0.01). The sites for the mono- and diphosphorylated MLC were identified as the monophosphorylated site Ser19 and diphosphorylated sites Ser19/Thr18 of MLC, respectively. Both types of MLC phosphorylations at the spastic segment were markedly inhibited by hydroxyfasudil (p<0.01). Conclusion: These results indicate that hydroxyfasudil-sensitive Rho-kinase-mediated pathway appears to mediate the enhanced MLC phosphorylations (on Ser19 and Ser19/Thr18 residues) and plays a central role in the pathogenesis of coronary artery spasm.

KEYWORDS Coronary vasospasm; Rho-kinase; Myosin light chain; Calcium


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
P. Y. Mong and Q. Wang
Activation of Rho Kinase Isoforms in Lung Endothelial Cells during Inflammation
J. Immunol., February 15, 2009; 182(4): 2385 - 2394.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
Y. Chiba, S. Nakazawa, M. Todoroki, K. Shinozaki, H. Sakai, and M. Misawa
Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Up-Regulation of RhoA Protein
Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 159 - 167.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Arita, Y. Hata, S. Nakao, T. Kita, M. Miura, S. Kawahara, S. Zandi, L. Almulki, F. Tayyari, H. Shimokawa, et al.
Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage
Diabetes, January 1, 2009; 58(1): 215 - 226.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Chiba, J. Arima, H. Sakai, and M. Misawa
Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L705 - L713.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.